Value
2.8/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 2.5 |
| Analyst target | 3.0 |
- ▸Expensive valuation
ESTA · Why this verdict
Why Establishment Labs Holdings (ESTA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceHIGH
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is expanding at 45% year-over-year, the highest growth rate in the peer group, positioning the company as the clear industry growth leader — a distinction that typically commands a durable premium as the market scales. Growth breakdown | Revenue growth stays above 30% YoY for at least 2 consecutive quarters, confirming that the expansion rate is not decelerating toward the peer average. | →Stable |
| CounterA 45% growth rate at this revenue scale is difficult to sustain; deceleration toward industry-average growth would erode the premium valuation that currently prices in continued outperformance. | ||
Despite strong top-line growth, free cash flow is negative at roughly 12% of revenue, meaning the company is consuming cash to fund its expansion and has not yet demonstrated that the growth model converts into self-funding economics. Quality breakdown | Free cash flow turns positive and stays above 0% of revenue for 2 consecutive quarters, confirming the business has reached cash generation inflection. | →Stable |
| CounterCash consumption during a high-growth investment phase is expected; if the company is deliberately deploying capital into markets with high returns, negative near-term free cash flow may be a rational trade-off. | ||
Short interest stands at 16% — a level the data characterizes as justified — reflecting meaningful market skepticism about whether the revenue growth translates into durable profitability at this valuation. Risk breakdown | Short interest falls below 8% as earnings demonstrate a path to profitability, reducing the supply of borrowed shares and the overhang that caps upside. | →Stable |
| CounterA heavily shorted stock with strong momentum can generate a short-covering rally that amplifies gains beyond what fundamentals alone would support, particularly if an earnings beat triggers covering. | ||
The company sources a critical material from a single silicone supplier, creating a supply chain concentration that could halt production or inflate costs if that relationship is disrupted. Bear case | Secondary supplier qualification is announced within 12 months, reducing single-source dependency and eliminating a hard operational ceiling on scale. | →Stable |
| CounterSingle-source supply arrangements are common during early growth phases of medical device companies; the risk may be manageable if the relationship is contractually protected and the supplier is financially stable. | ||
Revenue is expanding at 45% year-over-year, the highest growth rate in the peer group, positioning the company as the clear industry growth leader — a distinction that typically commands a durable premium as the market scales.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 30% YoY for at least 2 consecutive quarters, confirming that the expansion rate is not decelerating toward the peer average.
CounterA 45% growth rate at this revenue scale is difficult to sustain; deceleration toward industry-average growth would erode the premium valuation that currently prices in continued outperformance.
Despite strong top-line growth, free cash flow is negative at roughly 12% of revenue, meaning the company is consuming cash to fund its expansion and has not yet demonstrated that the growth model converts into self-funding economics.
→StableQuality breakdown
- Expectation
- Free cash flow turns positive and stays above 0% of revenue for 2 consecutive quarters, confirming the business has reached cash generation inflection.
CounterCash consumption during a high-growth investment phase is expected; if the company is deliberately deploying capital into markets with high returns, negative near-term free cash flow may be a rational trade-off.
Short interest stands at 16% — a level the data characterizes as justified — reflecting meaningful market skepticism about whether the revenue growth translates into durable profitability at this valuation.
→StableRisk breakdown
- Expectation
- Short interest falls below 8% as earnings demonstrate a path to profitability, reducing the supply of borrowed shares and the overhang that caps upside.
CounterA heavily shorted stock with strong momentum can generate a short-covering rally that amplifies gains beyond what fundamentals alone would support, particularly if an earnings beat triggers covering.
The company sources a critical material from a single silicone supplier, creating a supply chain concentration that could halt production or inflate costs if that relationship is disrupted.
→StableBear case
- Expectation
- Secondary supplier qualification is announced within 12 months, reducing single-source dependency and eliminating a hard operational ceiling on scale.
CounterSingle-source supply arrangements are common during early growth phases of medical device companies; the risk may be manageable if the relationship is contractually protected and the supplier is financially stable.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Establishment Labs is the industry's growth leader with 45% year-over-year revenue expansion and strong price momentum, but negative free cash flow, a 16% short interest, and a stock that has reached its near-term target with negative downside asymmetry make this a high-risk setup where the growth story is not yet matched by financial sustainability.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.9 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 5.5 |
| Piotroski F | 5.6 |
- ▸Cash-burning: FCF -12% of revenue
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 45% YoY
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 7.1 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.0 |
| Price target | 5.3 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Heavy insider selling — $33,230,996 (1.265% of mkt cap)
Peer rank
2.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.1 |
| quality rank | 1.3 |
| growth rank | 9.2 |
- ▸Industry growth leader
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 0.7 |
| 52w position | 9.7 |
| gap | 5.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 2.2 |
| volatility | 1.6 |
| put call | 10.0 |
| implied vol | 2.8 |
| beta | 6.7 |
| debt equity | 0.0 |
- ▸High short interest justified: 17%
- ▸High IV: 63%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:6.2>=5.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-0.7=NEGATIVE
- INSIDER:1.26%=EXTREME
Warning (0)
none
Reward-to-Risk
-0.74
Upside
-11.1%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 60, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.6B<$5B
Investment implication
The F-path SELL output reflects an overall score of 3.6 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.7=NEGATIVE, INSIDER:1.26%=EXTREME) reinforce the read. Current asymmetry R:R is -0.74 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Catalyst at 6.4, and Sentiment at 6.3; the weakest are Value at 2.8, Peer rank at 2.9, and Insider at 3.0. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of -0.74 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Industry Leading Revenue Growth
Trip ifRevenue growth falls below 20% YoY for 2 consecutive quarters.
- P2Negative Free Cash Flow Sustainability
Trip ifFree cash flow turns positive and exceeds 5% of revenue for 2 consecutive quarters.
- P3High Short Interest Skepticism
Trip ifShort interest falls below 8% of shares outstanding.
- P4Single Source Supply Chain Risk
Trip ifThe number of qualified silicone suppliers disclosed in an SEC filing rises above 1 in any annual or quarterly report, eliminating single-source dependency.